Exelixis Inc
NASDAQ:EXEL

  • LAST PRICE
    22.4700
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    17.0000/ 1
  • Ask / Lots
    24.5500/ 8
  • Open / Previous Close
    0.0000 / 22.4700
  • Day Range
    ---
  • 52 Week Range
    18.6400
    24.3400
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Jun 27, 2024

      Show headlines and story abstract

    • 3:28PM ET on Thursday Jun 27, 2024 by PR Newswire
      Companies Mentioned: EXEL, GSK, ONCY, GH

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.

      USA News GroupNews Commentary - According to the American Cancer Society, 2024 will be the first year the USA expects to have more than 2 million new cancer cases. In order to respond to the rising rates of cancer, the National Cancer Institute is making calls for changein how cancer clinical research is performed "Because our patients can't wait." According to Spherical Insights, the Global Oncology Drugs Marketis projected to grow by 11.5% CAGR through 2033 to US$564.5 billion, highlighting the need for more effective therapies and incentives for those who develop them. The biotech sector is actively addressing this need, with recent notable developments from several companies, including: Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), GSK plc (NYSE: GSK), Guardant Health, Inc. (NASDAQ: GH), Exelixis, Inc. (NASDAQ: EXEL), and Gilead Sciences, Inc. (NASDAQ: GILD).

Peers Headlines